The clinical manifestations of acute infection with Coxsackie B virus are varied and include epidemic pleurodynia, myopericarditis, meningoencephalitis, and pancreatitis. In most cases the infection is self limiting and does not result in chronic tissue damage, but it has also been associated with the development of polymyositis,l cardiomyopathy,' and diabetes mellitus.3 Arthritis is not widely recognised as either an acute or a chronic manifestation of infection with Coxsackie virus, and only one series, of six patients, has been reported previously.4 We report on three further patients, who developed febrile seronegative arthritis in association with clinical and serological evidence of Coxsackie infection; one subsequently developed a progressive erosive polyarthritis.
(83% neutrophils); antibody titres to Coxsackie B4 showed a diagnostic rise (table) . All Arsenic was widely used in the past to treat neurological disease, especially epilepsy and neurosyphilis, and psoriasis. Its use was limited by frequent toxic side effects, and most patients developed hyperkeratotic dermatitis, which occasionally progressed to squamous carcinoma. Other tumours occur after prolonged exposure, and tumours of the nasopharynx and bronchus and haemangiosarcoma of the liver are well recognised. More recently arsenic has been implicated in the development of non-cirrhotic portal hypertension.1 2 In the 1940s and 1950s a trial of arsenical drugs in multiple sclerosis was conducted in Birmingham.3 We report on a patient with possible long term sequelae of this treatment.
Case report
In 1957 a 32 year old car delivery man presented with recurrent transient neurological disturbances including paraplegia, blindness, cerebellar ataxia, and monoparesis. Multiple sclerosis was diagnosed. He was entered into the arsenic trial and received alternate-day injections of neoarsphenamine (sodium 3-amino-4,4-dihydroxy-3-sulphinomethylaminoarsenobenzene) for three months and Fowler's Solution (arsenic trioxide 1%) by mouth, which he continued to take daily for four years until his skin became "grey and scaly." In 1967 haematuria led to the diagnosis and treatment of a transitional cell tumour of the bladder. Later that year he presented with the first of 32 major gastrointestinal haemorrhages.
In 1969, during a severe haemorrhage not responding to conservative measures, emergency laparotomy was performed. No ulcer was seen, gastric erosions were noted, and the left gastric artery was ligated. Six months later laparotomy for severe haematemesis produced similar findings, and a Polya gastrectomy was performed. Subsequently liver biopsy specimens repeatedly showed a normal histological appearance. Splenoportal venography in 1974 showed a dilated tortuous portal vein and gastric and oesophageal varices but no extrahepatic obstruction to portal blood flow. Results of liver function tests remained normal. Over the next two years he underwent repeated endoscopic sclerotherapy of the varices and had no further haemorrhages. He had few neurological symptoms attributable to multiple sclerosis, and examination showed optic atrophy. The spleen was just palpable, and cystoscopy showed no residual tumour.
Comment
Non-cirrhotic portal hypertension is rare in the United Kingdom and the aetiology usually unknown. Arsenic and vinyl chloride monomer are well recognised aetiological agents. In India environmental exposure to arsenic is more common, and so is non-cirrhotic portal hypertension.2 Neoarsphenamine, with an amino-substituted benzene ring, has a similar structure to -2-naphthylamine and other organic dyes that cause transitional cell tumours of the bladder.
We suggest that non-cirrhotic portal hypertension in this patient was the direct result of administration of inorganic arsenic and that the bladder tumour was caused by neoarsphenamine. The coincidence of these complications in our patient suggests that other patients similarly treated in this trial may develop one or other lesion. (Godart Pulmotest) . The exercise test consisted of steady static running on a treadmill at submaximal work loads for up to eight minutes under controlled conditions of temperature and humidity. The study was carried out in a random single blind fashion using saline (9 g/l), sodium cromoglycate nebuliser solution (10 g/l), verapamil (2-5 g/l), and sodium cromoglycate plus verapamil. The drugs were delivered through a Wright nebuliser driven by compressed air at 8 1/min. Saline, sodium cromoglycate, and verapamil were inhaled for five minutes at tidal breathing; the combination of sodium cromoglycate and verapamil was inhaled for 10 minutes. The estimated nebulised dose of sodium cromoglycate and verapamil was 12 mg and 3 mg respectively. The nebulised dose of the combination contained 12 mg sodium cromoglycate and 3 mg verapamil. Spirometry was repeated at 30 minutes after inhalation and then at two, five, 10, 15, and 30 minutes after exercise. The results of the tests were expressed as the maximal percentage fall in forced expiratory volume in one second from the baseline value after the drug had been taken; they were analysed with Student's paired t test.
The table shows the results. There was no significant difference between the mean baseline values of forced expiratory volume in one second before and after inhalations of saline, sodium cromoglycate, and verapamil on four days of exercise testing. After exercise the mean maximal percentage falls in forced expiratory volume in one second after saline, sodium cromoglycate, verapamil, and sodium cromoglycate plus verapamil were  12-6±2-4, 8-8±2-0, and 5-3-:L11 respectively. The inhibitory effects of sodium cromoglycate and verapamil were significant, and no significant difference was found between the two treatments. The inhibitory effect of the combination of sodium cromoglycate and verapamil was greater than that of sodium cromoglycate alone (p < 0-02) but not significantly different from that of verapamil alone. Considerable intrasubject variability in response to verapamil and sodium cromoglycate was observed.
Sodium cromoglycate alone, verapamil alone, and the combination of these drugs significantly inhibited exercise induced asthma in the patients studied. Although the combination was superior to sodium cromoglycate alone, the results do not support potentiation or a summation effect. Foreman and Garland4 postulated that sodium cromoglycate may act on the calcium entry pathway. The variability of responses to verapamil and sodium cromoglycate in individual patients may suggest that the site of action of these drugs in exercise induced asthma is different; it is difficult to postulate whether their action is on mast cell degranulation or bronchial smooth muscle. 
